ALK-Abelló A/S (AKBLF)
USD 21.35
(-4.47%)
USD 21.35
(-4.47%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.36 Billion DKK | 2.07% |
| 2022 | 2.32 Billion DKK | 10.31% |
| 2021 | 2.1 Billion DKK | 12.09% |
| 2020 | 1.87 Billion DKK | -2.34% |
| 2019 | 1.92 Billion DKK | 11.16% |
| 2018 | 1.72 Billion DKK | 0.41% |
| 2017 | 1.72 Billion DKK | 17.22% |
| 2016 | 1.46 Billion DKK | 2.01% |
| 2015 | 1.44 Billion DKK | 4.05% |
| 2014 | 1.38 Billion DKK | -2.26% |
| 2013 | 1.41 Billion DKK | -6.53% |
| 2012 | 1.51 Billion DKK | 5.35% |
| 2011 | 1.43 Billion DKK | 11.04% |
| 2010 | 1.29 Billion DKK | 10.49% |
| 2009 | 1.17 Billion DKK | 2.99% |
| 2008 | 1.13 Billion DKK | 21.71% |
| 2007 | 935 Million DKK | -0.43% |
| 2006 | 939 Million DKK | 17.08% |
| 2005 | 802 Million DKK | 0.0% |
| 2004 | - DKK | 0.0% |
| 2003 | - DKK | 0.0% |
| 2002 | - DKK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 605 Million DKK | 5.24% |
| 2024 Q1 | 573 Million DKK | -11.85% |
| 2023 Q3 | 538 Million DKK | -11.8% |
| 2023 Q2 | 610 Million DKK | 6.83% |
| 2023 Q1 | 571 Million DKK | -9.79% |
| 2023 FY | 2.36 Billion DKK | 2.07% |
| 2023 Q4 | 650 Million DKK | 20.82% |
| 2022 FY | 2.32 Billion DKK | 10.31% |
| 2022 Q3 | 572 Million DKK | -3.38% |
| 2022 Q1 | 524 Million DKK | -15.76% |
| 2022 Q2 | 592 Million DKK | 12.98% |
| 2022 Q4 | 633 Million DKK | 10.66% |
| 2021 Q3 | 504 Million DKK | -1.95% |
| 2021 FY | 2.1 Billion DKK | 12.09% |
| 2021 Q4 | 622 Million DKK | 23.41% |
| 2021 Q2 | 514 Million DKK | 10.78% |
| 2021 Q1 | 464 Million DKK | -20.95% |
| 2020 Q3 | 422 Million DKK | 0.48% |
| 2020 FY | 1.87 Billion DKK | -2.34% |
| 2020 Q1 | 448 Million DKK | -17.19% |
| 2020 Q2 | 420 Million DKK | -6.25% |
| 2020 Q4 | 587 Million DKK | 39.1% |
| 2019 FY | 1.92 Billion DKK | 11.16% |
| 2019 Q3 | 464 Million DKK | 0.65% |
| 2019 Q4 | 541 Million DKK | 16.59% |
| 2019 Q2 | 461 Million DKK | 1.1% |
| 2019 Q1 | 456 Million DKK | -11.46% |
| 2018 Q1 | 393 Million DKK | -23.69% |
| 2018 FY | 1.72 Billion DKK | 0.41% |
| 2018 Q3 | 393 Million DKK | -7.09% |
| 2018 Q2 | 423 Million DKK | 7.63% |
| 2018 Q4 | 515 Million DKK | 31.04% |
| 2017 FY | 1.72 Billion DKK | 17.22% |
| 2017 Q4 | 515 Million DKK | 31.04% |
| 2017 Q3 | 393 Million DKK | -6.65% |
| 2017 Q2 | 421 Million DKK | 7.12% |
| 2017 Q1 | 393 Million DKK | -4.38% |
| 2016 Q2 | 379 Million DKK | 9.22% |
| 2016 Q4 | 411 Million DKK | 23.8% |
| 2016 Q3 | 332 Million DKK | -12.4% |
| 2016 FY | 1.46 Billion DKK | 2.01% |
| 2016 Q1 | 347 Million DKK | -14.32% |
| 2015 Q4 | 405 Million DKK | 22.73% |
| 2015 Q1 | 339 Million DKK | -12.4% |
| 2015 Q2 | 366 Million DKK | 7.96% |
| 2015 FY | 1.44 Billion DKK | 4.05% |
| 2015 Q3 | 330 Million DKK | -9.84% |
| 2014 Q4 | 387 Million DKK | 22.47% |
| 2014 FY | 1.38 Billion DKK | -2.26% |
| 2014 Q3 | 316 Million DKK | -10.99% |
| 2014 Q2 | 355 Million DKK | 8.9% |
| 2014 Q1 | 326 Million DKK | -0.31% |
| 2013 Q2 | 389 Million DKK | 3.46% |
| 2013 FY | 1.41 Billion DKK | -6.53% |
| 2013 Q3 | 324 Million DKK | -16.71% |
| 2013 Q1 | 376 Million DKK | -1.05% |
| 2013 Q4 | 327 Million DKK | 0.93% |
| 2012 Q3 | 355 Million DKK | -12.56% |
| 2012 Q2 | 406 Million DKK | 8.56% |
| 2012 Q1 | 374 Million DKK | -6.03% |
| 2012 Q4 | 380 Million DKK | 7.04% |
| 2012 FY | 1.51 Billion DKK | 5.35% |
| 2011 Q4 | 398 Million DKK | 23.22% |
| 2011 Q2 | 330 Million DKK | 52.78% |
| 2011 Q3 | 323 Million DKK | -2.12% |
| 2011 Q1 | 216 Million DKK | -51.68% |
| 2011 FY | 1.43 Billion DKK | 11.04% |
| 2010 FY | 1.29 Billion DKK | 10.49% |
| 2010 Q3 | 322 Million DKK | -2.42% |
| 2010 Q1 | 289 Million DKK | 25.11% |
| 2010 Q4 | 447 Million DKK | 38.82% |
| 2010 Q2 | 330 Million DKK | 14.19% |
| 2009 FY | 1.17 Billion DKK | 2.99% |
| 2009 Q4 | 231 Million DKK | -16.91% |
| 2009 Q3 | 278 Million DKK | -3.47% |
| 2009 Q2 | 288 Million DKK | 2.13% |
| 2009 Q1 | 282 Million DKK | 0.0% |
| 2008 FY | 1.13 Billion DKK | 21.71% |
| 2007 FY | 935 Million DKK | -0.43% |
| 2006 FY | 939 Million DKK | 17.08% |
| 2005 FY | 802 Million DKK | 0.0% |
| 2004 FY | - DKK | 0.0% |
| 2003 FY | - DKK | 0.0% |
| 2002 FY | - DKK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 10.86 Million USD | -21699.945% |
| Skye Bioscience, Inc. | 13.54 Million USD | -17386.557% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -6258.763% |
| Nascent Biotech, Inc. | 2.22 Million USD | -106138.948% |
| Qrons Inc. | 643.67 Thousand USD | -367941.735% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -570085.256% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -46884.913% |
| BioStem Technologies, Inc. | 22.97 Million USD | -10211.297% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -256421.315% |
| CSL Limited | 3.44 Billion USD | 31.313% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -4024.304% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -7916.107% |
| Rebus Holdings, Inc. | 664 Thousand USD | -356677.108% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -177295.912% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -608012.618% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -14696.783% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -2629.734% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -48070.84% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -905045.075% |
| SQZ Biotechnologies Company | 85.61 Million USD | -2666.909% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -81134.88% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -157633.643% |
| Mesoblast Limited | 5.9 Million USD | -40038.936% |
| Marizyme, Inc. | 19.23 Million USD | -12212.997% |
| Genus plc | 147.7 Million USD | -1503.927% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -26884.131% |
| Pharming Group N.V. | 225.49 Million USD | -950.596% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -115534.022% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -176487.442% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -28308.682% |
| ContraFect Corporation | 56.88 Million USD | -4064.25% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -53635.002% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -160102.657% |
| IMV Inc. | 37.7 Million USD | -6182.284% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -84799.531% |
| MultiCell Technologies, Inc. | 567.42 USD | -417503689.08% |
| ONE Bio Corp. | 6.44 Million USD | -36663.496% |
| Accustem Sciences Inc. | 3.74 Million USD | -63133.717% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -2656.414% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -445232.561% |
| Q BioMed Inc. | 3.43 Million USD | -68833.85% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -9485.272% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -90060.996% |
| Biomind Labs Inc. | 994.18 Thousand USD | -238186.35% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -2284.975% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -134526.903% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -35163.393% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -126967.052% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 9476100.0% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -128994.134% |
| GB Sciences, Inc. | 1.42 Million USD | -166671.207% |
| Alpha Cognition Inc. | 9.7 Million USD | -24308.586% |
| HST Global, Inc. | 140.9 Thousand USD | -1681150.754% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -210494.625% |
| Halberd Corporation | 74.84 Thousand USD | -3165234.972% |
| Enzolytics Inc. | 2.17 Million USD | -108594.306% |
| Agentix Corp. | 1.37 Million USD | -172598.352% |
| Resverlogix Corp. | 12.71 Million USD | -18535.935% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -64791.54% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | -54.48% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -226815.709% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -98405.822% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -149897.942% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -69474.585% |
| AVAX Technologies, Inc. | 7.31 Million USD | -32306.49% |
| Zenith Capital Corp. | 8.94 Million USD | -26389.992% |
| Genscript Biotech Corporation | 825.34 Million USD | -187.032% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -13598430.509% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -96384.487% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1381168.621% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -123227.222% |
| Kadimastem Ltd | 2.41 Million USD | -98194.187% |
| Helix BioMedix, Inc. | 1.97 Million USD | -120029.775% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1305242.039% |
| LadRx Corporation | 3.81 Million USD | -62049.263% |
| Cell Source, Inc. | 4.32 Million USD | -54670.185% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -256421.315% |
| NovAccess Global Inc. | 2.46 Million USD | -95936.868% |
| Affymax, Inc. | 39.38 Million USD | -5914.828% |
| Itoco Inc. | 919.14 Thousand USD | -257640.09% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -55793.549% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -211606.881% |
| Mobile Lads Corp. | 554.54 Thousand USD | -427096.301% |
| CytoDyn Inc. | 18.05 Million USD | -13018.839% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -9412272.363% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1076336.536% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -166755.427% |
| SYBLEU INC | 160.87 Thousand USD | -1472462.719% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -130328.559% |
| International Stem Cell Corporation | 5.27 Million USD | -44844.033% |
| Bioxytran, Inc. | 3.82 Million USD | -61913.32% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -4500108.959% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -11645183.39% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -6432.289% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -146315.328% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -321847.176% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -76049.148% |
| Neutra Corp. | 243.82 Thousand USD | -971514.422% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -13470.487% |
| PureTech Health plc | 144.59 Million USD | -1538.347% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -11461.801% |
| IXICO plc | 4.7 Million USD | -50229.297% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -26829.635% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -1911.924% |
| CSL Limited | 3.89 Billion USD | 39.147% |
| Cellectis S.A. | 97.32 Million USD | -2334.238% |